Incepta Pharmaceuticals Ltd: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from Incepta Pharmaceuticals Ltd?

Yes. FDA’s import refusal records list 5 refused shipment lines declared as made by Incepta Pharmaceuticals Ltd (Bangladesh) whose FDA product code names semaglutide, from Jun 26, 2024 to Feb 7, 2026. None of them carries a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Spellings in FDA records
Incepta Pharmaceuticals Ltd; INCEPTA PHARMACEUTICALS; INCEPTA PHARMACEUTICALS LTD
Country
Bangladesh
City in FDA records
Dhaka
FEI numbers on the lines
3007306071, 3038731173, 3018092119
Refused lines
5
Lines with an Import Alert 66-80 API or powder code
0
Drugs named in the product codes
Semaglutide
Refusal dates
Jun 26, 2024 to Feb 7, 2026

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Incepta Pharmaceuticals Ltd is on it.

Refused shipment lines

FDA refusal chargesShipment ID
Feb 7, 2026Bangladesh61PCP72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).799-8328738-7/10002/1
Sep 24, 2025Bangladesh61PCY72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).AEK-7364558-0/12/1
May 2, 2025Bangladesh61PCY72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).AEK-8456378-0/11/1
Oct 8, 2024Bangladesh61PCM72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).SCS-6288609-2/11/1
Jun 26, 2024Bangladesh61PCY72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).SCS-4456039-3/11/1

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).5

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

5 lines from FDA files read Nov 15, 2026.